Opsocrom2%

Opsocrom eye drops are indicated for the prophylactic treatment and relief of the signs and symptoms of allergic conjunctivitis, including seasonal (hay fever-related) and perennial (year-round) allergic conjunctivitis.

Evidence-based classification of use

• Established/labeled use: Prevention and symptomatic relief of allergic conjunctivitis (itching, redness, watering, and irritation of the eyes caused by allergens such as pollen, dust, or animal dander).
• Related uses of the drug class (different formulations, not this ophthalmic 2% product): Sodium cromoglicate as a class is also used as a nasal spray for allergic rhinitis and as an inhaled formulation for prophylaxis of bronchial asthma. These are separate dosage forms and are not covered by this ophthalmic 2% preparation.

Opsocrom works best when started before expected allergen exposure (e.g., before the pollen season) and used regularly; it is a preventive treatment and is not intended for rapid relief of an allergic reaction that has already started.

Each mL of Sodium Cromoglicate [2%] ophthalmic solution contains sodium cromoglicate 20 mg (2% w/v) as the active ingredient.

Common excipients include benzalkonium chloride (preservative) and a buffered aqueous vehicle. Exact excipient composition may vary by manufacturer; refer to the product packaging for full details.

Opsocrom is an ophthalmic (eye drop) preparation of sodium cromoglicate, a mast cell stabilizer used in the prophylaxis and treatment of allergic conjunctivitis. It belongs to a class of medicines known as anti-allergic/mast cell-stabilizing agents.

Unlike antihistamine eye drops that act on already-released mediators, Opsocrom works upstream by preventing mast cells from releasing histamine and other inflammatory mediators when they encounter an allergen, which is why regular preventive use gives the best results.

Opsocrom belongs to the therapeutic class of mast cell stabilizers (anti-allergic ophthalmic agents), distinct from ophthalmic antihistamines, corticosteroids, and NSAIDs used in ocular allergy.

Mechanism of action

Sodium Cromoglicate [2%] stabilizes the membrane of sensitized mast cells, inhibiting the degranulation that occurs when these cells are exposed to specific antigens. This action prevents the release of histamine and other mediators of the allergic response (such as leukotrienes) from mast cells following exposure to allergens.

Pharmacokinetics

Following ocular administration, systemic absorption of Sodium Cromoglicate [2%] is minimal; a small fraction of the topically applied dose may reach systemic circulation via nasolacrimal drainage and conjunctival/nasal mucosal absorption. The drug is not significantly metabolized and is excreted largely unchanged in bile and urine.

Sodium Cromoglicate [2%] has no intrinsic anti-histaminic, anti-inflammatory (in the corticosteroid sense), or vasoconstrictor activity; its benefit is entirely preventive, via mast cell stabilization.

How to use Opsocrom eye drops

• Wash hands before use. Tilt the head back, pull down the lower eyelid gently to form a small pocket, and instill the prescribed number of drops without letting the dropper tip touch the eye, eyelid, or any other surface.
• Close the eye gently for 1–2 minutes after instillation and apply light pressure to the inner corner of the eye (near the nose) to reduce systemic absorption.
• If using another eye drop product at the same time, wait at least 5 minutes between different eye medications.
• Contact lenses: Soft contact lenses should not be worn during treatment because of possible absorption of the preservative (benzalkonium chloride) into the lens. Other types of contact lenses should be removed before instillation and not reinserted for at least 15 minutes.
• Discard the bottle 28 days after first opening, even if solution remains, and do not use if the solution is discolored or cloudy.

Opsocrom has minimal systemic absorption when used as eye drops, and no clinically significant drug-drug interactions are well established for this ophthalmic formulation.

As a general precaution, if using more than one topical eye medication, space administration by at least 5 minutes to prevent one drop from washing out another and to allow adequate absorption of each product. There is no known interaction requiring dose adjustment with systemic medications when Opsocrom eye drops are used as directed.

Opsocrom is generally very well tolerated. The most commonly reported side effects are local and transient:

• Transient stinging, burning, or discomfort immediately after instillation
• Temporary blurring of vision
• Mild eye redness or irritation

Rarely, hypersensitivity reactions (e.g., eyelid swelling, itching, or contact dermatitis) can occur, in which case use should be stopped and a physician consulted. Serious adverse effects are uncommon given the drug's minimal systemic absorption.

Opsocrom has a generally favorable safety profile in pregnancy due to its minimal systemic absorption when used topically in the eye, and animal reproduction studies have not shown evidence of fetal harm. However, as with any medication, Opsocrom should be used during pregnancy only if clearly needed, and the potential benefit should be weighed against any potential risk; a physician should be consulted before use.

Systemic absorption after ocular use is very low, making clinically significant transfer into breast milk unlikely; nonetheless, breastfeeding mothers should consult a physician before using Opsocrom.

• Opsocrom is a preventive (prophylactic) medication, not a rescue treatment. It does not provide immediate relief once an allergic reaction has already started, and consistent regular use before and during allergen exposure is necessary for maximum benefit.
• If eye symptoms persist beyond 48 hours of regular treatment, worsen, or are accompanied by eye pain, visual disturbance, or suspected eye injury/trauma, discontinue use and seek prompt medical advice — do not self-treat a possible eye infection or injury with Opsocrom.
• Avoid touching the dropper tip to the eye or any surface to prevent contamination of the solution.
• Soft contact lenses should not be worn during treatment; see Administration for contact lens guidance.
• Discard opened containers after 28 days and do not use if the solution appears discolored or cloudy.
• For external ophthalmic use only; not for injection or oral use.

Overdose with Opsocrom eye drops is unlikely given the small volume administered and minimal systemic absorption. Accidental ocular over-instillation is generally not expected to cause serious harm beyond transient local irritation.

If accidental ingestion of the bottle contents occurs, or if any serious or unexpected symptoms develop, seek immediate medical attention or contact a poison control center; general supportive and symptomatic treatment should be provided as clinically indicated.

Store below 30°C, away from direct light and moisture. Do not freeze. Discard the bottle 28 days after first opening. Do not use if the solution is discolored or cloudy. Keep out of reach of children.

Elderly

No dosage adjustment is required for elderly patients using Opsocrom.

Renal and hepatic impairment

Because systemic absorption after ocular administration of Opsocrom is minimal, specific dosage adjustment in renal or hepatic impairment is not well established as necessary; use with routine caution and physician guidance in patients with significant organ impairment.

Children

Opsocrom is indicated for children over 6 years of age at the same dose as adults. Use in children under 6 years should only be undertaken on medical advice, as safety and efficacy have not been well established for this age group with this product.

Opsocrom is intended for regular, ongoing preventive use throughout the period of allergen exposure (for example, throughout a pollen season), rather than for short-term or as-needed relief. Noticeable improvement typically requires several days of consistent use.

Continuous use beyond 4 weeks should only continue under medical supervision, and a physician should periodically review the need for continued treatment.

Sodium Cromoglicate [2%] belongs to the drug class of mast cell stabilizers, also referred to as anti-allergic ophthalmic agents. Other members of this pharmacological class (used in different formulations) include lodoxamide and nedocromil.

Sodium Cromoglicate [2%] acts by stabilizing the membranes of sensitized mast cells in the conjunctiva, preventing calcium influx-dependent degranulation that would otherwise occur on re-exposure to a specific allergen. By blocking this degranulation, it prevents the release of histamine, leukotrienes, and other inflammatory mediators responsible for the itching, redness, and watering of allergic conjunctivitis.

B (FDA legacy pregnancy category, based on ophthalmic cromolyn sodium formulations)

Opsocrom is approved for use in children over 6 years of age, at the same dose as adults (1–2 drops in each eye, 4 times daily).

For children under 6 years of age, safety and efficacy of this specific ophthalmic product have not been well established; use in this age group should only occur under direct medical supervision and advice.